The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy

British Journal of Radiology

Volumn 85, Issue 1019, 2012, Pages

  Sherriff, J M ^a   Ogunremi, B ^a   Colley, S ^a   Sanghera, P ^a   Hartley, A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG TUMOR LEVEL; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; IMAGE ANALYSIS; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIMODAL CHEMOTHERAPY; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; RADIATION DOSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84868005520     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/20976707     Document Type: Article

References (23)

1. Boyd TS, Harari PM, Tannehill SP, Voytovich MC, Hartig GK, Ford CN, et al. Planned post-radiotherapy neck dissection in patients with advanced head and neck cancer. Head Neck 1998;20:132-7. (Pubitemid 28106225)
2. Langerman A, Plein C, Vokes EE, Salama JK, Haraf DJ, Blair EA, et al. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1133-6.
3. Higgins KA, Hoang JK, Raoch MC, Chino J, Yoo DS, Turkington TG, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUV (mean) has superior prognostic value. Int J Radiat Oncol Biol Phys 2012;82:548-53.
4. Schinagl DA, Span PN, Oyen WJ, Kaanders JH. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 2011;38:1449-58.
5. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1085-93.
6. Mori M, Tsukuda M, Horiuchi C, Matsuda H, Taguchi T, Takahashi M, et al. Efficacy of fluoro-2-deoxy-D-glucose positron emission tomography to evaluate responses to concurrent chemoradiotherapy for head and neck squamous cell carcinoma. Auris Nasus Larynx 2011;38:724-9.
7. Loo SW, Geropantas K, Beadsmoore C, Montgomery PQ, Martin WM, Roques TW. Neck dissection can be avoided after sequential chemoradiotherapy and negative posttreatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma. Clin Oncol (R Coll Radiol) 2011;23:512-17.
8. Tan A, Adelstein DJ, Rybicki LA, Saxton JP, Esclamado RM, Wood BG, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007;133:435-40. (Pubitemid 46799778)
9. Yao M, Smith RB, Hoffman HT, Funk GF, Lu M, Menda Y, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74:9-14.
10. Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008;49:532-40. (Pubitemid 351520600)
11. Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, et al. Does 18F-FDG PET/CT improve the detection of post treatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9.
12. Nayak JV, Walvekar RR, Andrade RS, Daamen N, Lai SY, Argiris A, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007;117:2129-34. (Pubitemid 351339585)
13. Gupta T, Jain S, Agarwal JP, Rangarajan V, Purandare N, Ghosh-Laskar S, et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo) radiation. Radiother Oncol 2010;97:194-9.
14. Schoder H, Fury M, Lee N, Kraus D. PET Monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50:74S-88S.
15. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Hossein-Foucher C, et al. European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardised uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
16. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol 2011;93:502-8.
17. Chennupati SK, Quon A, Kamaya A, Pai RK, La T, Krakow TE, et al. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Am J Clin Oncol 2012;35:334-9. E-pub ahead of print Mar. 2011.
18. Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am J Clin Oncol 2012;35:340-4. E-pub ahead of print Mar. 2011.
19. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-22. (Pubitemid 351799005)
20. Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010;21:1515-22.
21. Vandecaveye V, Dirix P, De Keyzer F, Op de Beeck K, Poorten VV, Hauben E, et al. Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:1098-107.
22. Sanghera P, Rampling R, Haylock B, Jefferies S, McBain C, Rees JH, et al. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (R Coll Radiol) 2012;24:216-27.
23. Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, et al Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33:1675-82.